Use of recombinant feline interferon and glucocorticoid in the treatment of feline infectious peritonitis | Zendy

Takafumi Ishida | Zendy; Akiko Shibanai | Zendy; Satoshi Tanaka | Zendy; Kazuyuki Uchida | Zendy; Masahito Mochizuki | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Use of recombinant feline interferon and glucocorticoid in the treatment of feline infectious peritonitis

Author(s) -

Takafumi Ishida,

Akiko Shibanai,

Satoshi Tanaka,

Kazuyuki Uchida,

Masahito Mochizuki

Publication year - 2004

Publication title -

journal of feline medicine and surgery

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.837

H-Index - 61

eISSN - 1532-2750

pISSN - 1098-612X

DOI - 10.1016/j.jfms.2003.08.011

Subject(s) - cats , feline infectious peritonitis , recombinant dna , medicine , peritonitis , glucocorticoid , interferon , gastroenterology , immunology , virology , infectious disease (medical specialty) , biology , covid-19 , disease , biochemistry , gene

A total of 12 clinically ill cats previously diagnosed as feline infectious peritonitis (FIP) were treated with a combination of recombinant feline interferon and glucocorticoid. A complete remission (over 2 years) and a partial remission (2 to 5 months) were observed in four (33.3%) and four (33.3%) cases, respectively. Those that survived for more than 2 years were all older cats (6 to 16 years old) with the effusive form of FIP.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research